Surveillance and Diagnosis of West Nile Virus in the Face of Flavivirus Cross-Reactivity

Yaniv Lustig1, Danit Sofer1, Efrat Dahan Bucris1 and Ella Mendelson1,2

1 Central Virology Laboratory, Ministry of Health, Sheba Medical Center, Ramat Gan, Israel. 2 School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

West Nile Virus (WNV) is an arthropod-borne flavivirus whose zoonotic cycle includes both mosquitoes and birds as amplifiers and humans and horses as dead-end hosts. In recent years WNV has been spreading globally and is currently endemic in Africa, The Middle East, India, Australia, central and southern Europe, and the Americas. Integrated surveillance schemes and environmental data aim to detect viral circulation and reduce the risk of infection for the human population emphasizing the critical role for One Health principles in public health. Approximately 20% of WNV infected patients develop West Nile Fever while in less than 1%, infection results in West Nile Neurological Disease. Currently, the diagnosis of WNV infection is primarily based on serology, since molecular identification of WNV RNA is unreliable due to the short viremia. The recent emergence of Zika virus epidemic in America and Asia has added another layer of complexity to WNV diagnosis due to significant cross-reactivity between several members of the Flaviviridae family such as Zika, dengue, Usutu, and West Nile viruses. Diagnosis is especially challenging in persons living in regions with flavivirus co-circulation as well as in travelers from WNV endemic countries traveling to Zika or dengue infected areas or vise-versa. Here, we review the recent studies implementing WNV surveillance of mosquitoes and birds within the One Health initiative. Furthermore, we discuss the utility of novel molecular methods, alongside traditional molecular and serological methods, in WNV diagnosis and epidemiological research.

Keywords: WNV, surveillance, one health, diagnosis, Zika, West Nile, mosquitoes, flavivirus

INTRODUCTION

West Nile Virus (WNV) is a member of the family Flaviviridae from the genus Flavivirus which also contain other viruses pathogenic to humans such as Zika, dengue, yellow fever, Usutu, and Japanese encephalitis (Hayes et al., 2005; Petersen et al., 2013). WNV is maintained in nature in a bird-mosquito cycle with birds acting as amplifying hosts (Malkinson and Banet, 2002). WNV infects mostly mosquitoes from the Culex genus which can potentially transmit the virus to every vertebrate on which they feed (Orshan et al., 2008; Andreadis, 2012; Engler et al., 2013; Steiner and Kennedy, 2013; Lustig et al., 2015). While many bird species do not develop any disease, several species such as crows and jays may die of WNV infection (Gamino and Hofle, 2013). Mammals, primarily horses and humans are unable to contribute to the transmission cycle and thus are considered dead end hosts (Colpitts et al., 2012).
West Nile Virus infection in humans is mostly asymptomatic, however, in approximately 20% of the cases WNV infection induces a mild disease with influenza like symptoms termed West Nile Fever (WNF), while in less than 1% of cases, mainly in elderly and immunocompromised people, infection results in a severe neuroinvasive disease (WNND) which may lead to death (Hayes et al., 2005). Horses are more prone to WNV than humans and 10% of infected horses may show neurological signs (Castillo-Olivares and Wood, 2004). Currently, no vaccine or other treatments are available for humans, although inactivated and recombinant vaccines are on the market for horses (Seino et al., 2007).

During the last 20 years WNV has spread geographically and is now common in countries in Africa, Europe, the Middle East, North America, and East Asia where it can cause disease outbreaks (Petersen et al., 2013). While the origin of all WNV lineages and genotypes is most probably Africa (May et al., 2011), WNV is primarily distributed to other areas by bird migration paths (Mackenzie et al., 2004). Such is the case for the introduction of WNV into Europe which is hypothesized to be mediated by birds migrating from Africa to Europe in the spring (Calistrri et al., 2010). According to two models, long distance WNV dispersal is dependent on birds while short distance diffusion of the virus is mediated by mosquitoes (Liu et al., 2006; Maida and Yang, 2009). Other factors contributing to WNV spread and its ability to cause human infection include short- and long-distance migratory species (Rappole and Hubalek, 2003), wind patterns (Mackenzie et al., 2004) and the existence of compatible mosquito vector. Studies in Israel, a major crossroad for bird migration between Africa and Eurasia, have indicated that four different genotypes within two lineages of WNV have been circulating in recent years (Lustig et al., 2015). Due to its complex transmission cycle and lack of treatment, it is now apparent that a multi-disciplinary approach with cross sectorial collaboration between organizations from public, animal and environmental health is needed to obtain knowledge on WNV prevalence and might be implemented in the whole country or restricted to specific region of high WNV endemicity. In the next sections we discuss eight WNV endemic countries which represent several levels of implementation of the One Health concept (Table 1).

### Italy

Following the first outbreak of WNV in horses in Italy in 1998 (Cantile et al., 2000; Autorino et al., 2002) the Italian government has started in 2001 a national surveillance plan that targeted birds, domestic poultry, horses, mosquitoes, and humans (Angelini et al., 2010). In recent years this plan, which is carried out in three regions in the Po valley area in northern Italy where WNV is endemic, has developed and is now based on the trans disciplinary and trans-sectorial collaboration between regional institutions involved in public, human, animal, and environmental health (Angelini et al., 2010; Mulatti et al., 2013; Napoli et al., 2013; Rosa et al., 2014; Calzolari et al., 2015). The integrated surveillance system also allows to modulate blood donations screening in the Emilia-Romagna region as only WNV detection by the surveillance system triggers public health interventions on blood donors (Paternoster et al., 2017a). To improve the surveillance sensitivity, data sharing mechanisms have been established among the three regions which are aimed at early detection of the viral circulation and reduction of the risk of infection (Paternoster et al., 2017b). Since WNV can be transferable through blood donations, seroprevalence of WNV antibodies among blood donors is also examined (Pezzotti et al., 2011; Pierro et al., 2011, 2013; Gaibani et al., 2013).

### Greece

West Nile Virus has emerged in Greece in 2010 and caused outbreaks for three consecutive years in both humans and horses (Papa et al., 2010; Danis et al., 2011a,b; Papa, 2012; Bouzalas et al., 2016). Following the 2010 outbreak a strategic framework for an integrated entomological surveillance program was established with the aims to address the impact of current vector control strategies and climate on mosquito population, to analyze the mosquito species composition in WNV affected areas as well as other areas of Greece and to quantify viral circulation, geographic spread and transmission cycle of WNV in mosquitoes (Gomes et al., 2013; Valiakos et al., 2014; Patsoula et al., 2016). In recent years seroprevalence studies in both humans (Ladbury et al., 2013; Vrioni et al., 2014), chickens (Chaintoutis et al., 2016), and equine (Bouzalas et al., 2016) were initiated to examine the kinetics of WNV prevalence in animals and humans over time.

### WNV SURVEILLANCE WITHIN THE ONE HEALTH INITIATIVE

The One Health concept recognizes that the health of humans, animals, and environment are all connected and that only a collaborative inter-disciplinary approach can effectively achieve optimal health outcomes (Lerner and Berg, 2015). WNV is transmitted to humans and animals primarily via the amplification of the mosquitoes – birds’ enzootic cycle which is independently controlled by climatic and environmental factors such as temperatures, seasons and water level fluctuations (Paz and Semenza, 2013). Therefore, active surveillance of WNV in mosquitoes and birds population in combination with analysis of climatic and environmental data offers an opportunity to detect virus prior to the emergence of disease in equine species or human populations and predict timing and locations of future WNV disease outbreaks. Most important, early detection of WNV may facilitate targeted use of insecticides in the infected area to reduce WNV burden in human and animal populations. The necessity of such surveillance schemes is dependent on WNV prevalence and might be implemented in the whole country or restricted to specific region of high WNV endemicity.
Spain was conducted with the hope to improve WNV risk-based regions. Recently, risk mapping of WNV circulation in 2015 in government and as such is focused on specific years and/or other private institutions and not by the Spanish or municipal primarily investigated as research projects run by universities and Jimenez-Clavero et al., 2014). Currently, surveillance of WNV in Spain is before the occurrence of cases in humans or horses (Figuerola Garcia-Bocanegra et al., 2011, 2012; Lopez-Ruiz et al., 2018). Nevertheless, monitoring of mosquitoes infected with WNV and screening of WNV seropositivity in humans, horses, and birds in Spain has enabled the detection of WNV circulation years only two outbreaks with two and three human patients have been recorded in Andalusia, in 2010 and 2016, respectively. In 1999–2016, national incidence of WNND cases varied from 30–39 year-olds to ≥70 years old. Median age was 64.7 in live cases and 75.6 in fatal cases (Salama et al., 2018). Canada conducts ongoing surveillance at the national level in humans, animals, and mosquitoes. COVID-19 surveillance and develop a model for WNV distribution and infection in Spain (Sanchez-Gomez et al., 2017).

Israel

West Nile Virus has been recognized as endemic in Israel since its establishment in 1948. However, despite sporadic cases and a few small outbreaks (Bernkopf et al., 1953; Flatau et al., 1981; Katz et al., 1989), WNV was not considered a public health concern until 2000, when a large scale human outbreak occurred (Bin et al., 2001; Weinberger et al., 2001). Since then outbreaks of varying magnitudes have been recorded every few years (Anis et al., 2014). Following the 2000 outbreak, a national mosquito surveillance system was established which is responsible for entomological analysis of mosquitoes and characterization of WNV circulation in Israel (Orshan et al., 2008; Lustig et al., 2015). Furthermore, WNV infections in humans and seropositivity of the population are monitored routinely and are integrated
with mosquito surveillance data by the public health division to assess the burden of WNV circulation in Israel and implement appropriate measures (Lustig et al., 2015, 2017a;b; Bassal et al., 2017). Recently, the public health and veterinary services, Israel Nature and Park Authorities and the ministry of environmental protection have initiated a program to integrate WNV data obtained from humans, mosquitoes, horses, and birds with the aim to develop a true one health initiative for WNV in Israel. Finally, testing of blood donors was initiated in 2017 to assess the extent of alternative routes of WNV transmission to humans in Israel.

**Turkey**

Much like its neighbor, Greece, WNV outbreaks emerged in 2010 and 2011 with 47 and 5 human cases, respectively (Kalaycioglu et al., 2012). Since then several seroprevalence and mosquito surveillance reports confirmed the presence of WNV in Turkey (Ergunay et al., 2013, 2014, 2015). A recent study was initiated to provide a risk-assessment of the circulation of mosquito borne flaviviruses in Turkey (Ergunay et al., 2017), however, an integrated national surveillance plan is not yet in place.

**Austria**

West Nile Virus was first identified in Austria in birds in 2008 (Bakonyi et al., 2013) and human infection has been recorded since 2009 (Stiasny et al., 2013). Since then several WNV clinical cases are diagnosed each year in humans (Gossner et al., 2017; Kolodziejek et al., 2018). In 2013, a national WNV task force was established which is responsible to integrate all data collected from mosquito surveillance systems, veterinary surveillance of birds and horses and the Austrian Blood Donation System and public health authorities (Gossner et al., 2017; Kolodziejek et al., 2018). Altogether, detailed reports of WNV activity in Austria are closely monitored (Kolodziejek et al., 2018).

**United States**

West Nile Virus had not been detected in North America before 1999, when a large WNV outbreak occurred in New York City (Nash et al., 2001). Phylogenetic studies identified genetic similarity to strains previously identified in Israel, suggesting a Middle Eastern importation (Lanciotti et al., 1999). Since then, the 1999 outbreak strain was rapidly displaced by a novel North American genotype (NA/WN02) (Davis et al., 2005) which can now be found in all 48 contiguous states and was responsible for large nationwide epidemics in 2003 and 2012 (Arnold, 2012; Roehrig, 2013). WNV can be transmitted under lab setting for large nationwide epidemics in 2003 and 2012 (Arnold, 2012; Davis et al., 2017). However, despite association of WNV outbreaks in the United States with parameters such as urban and ecological habitats (Bowden et al., 2011), rural irrigated landscapes (DeGroote and Sugumaran, 2012), increased temperature (Hartley et al., 2012), several socioeconomic factors such as housing age and community drainage patterns (Ruiz et al., 2007), per capita income (DeGroote and Sugumaran, 2012), and neglected swimming pool density (Reisen et al., 2008; Harrigan et al., 2010), no models have been developed that predict how these factors combine to produce outbreaks. Since the Zika virus outbreak in 2015, ArboNET is routinely used for Zika disease reporting, thus allowing the quick integration and dissemination of data across the United States (Simeone et al., 2016).

**Canada**

Following WNV introduction to the United States, the virus has spread to Canada and was responsible for major outbreaks in 2002 and 2012 in Ontario and Quebec and in 2003 and 2007 in the Prairie Provinces (Zheng et al., 2014; Kulkarni et al., 2015). In order to cope with the disease, integrated mosquito surveillance is routinely performed at the national level and WNV disease is nationally notifiable and reportable (Zheng et al., 2014). In addition, surveillance data on humans, horses, and birds is shared between all municipalities and blood donations are routinely checked for WNV RNA presence. Data assembly into weekly national reports and studies evaluating the dynamics of WNV transmission using human case prevalence, mosquito surveillance, and climate data (Chen et al., 2013; Giordano et al., 2017; Mallya et al., 2018) contribute to raising the awareness of WNV in Canada.

**Assessment of One Health Initiatives**

At this point it is hard to assess the effects that One Health initiatives have on controlling WNV disease in each country. In Italy, an unbiased quantitative evaluation protocol has been developed to examine the implementation of the One Health approach in order to “fine tune” the system (Paternoster et al., 2017b). However, since One Health is a relatively young approach more time is needed to retrospectively examine its effect on reduction of WNV circulation and infection.

**WNV RNA DIAGNOSIS**

With the development of molecular biology methods in the 1980s, laboratory diagnosis of viral infections have developed from traditional viral isolation in cell culture which can take days to weeks (Leland and Ginocchio, 2007) to molecular detection of viral genomes which can be achieved in hours. Acute WNV infection in humans can be diagnosed by WNV RNA detection in samples obtained from symptomatic patients. In addition, since WNV can be transferable through blood...
Lustig et al. Surveillance and Diagnosis of West Nile Virus

FIGURE 1 | Theoretical depiction of WNV presence in body fluids and WNV immune response. The phases of WNV detection period in serum, urine, and whole blood as well as the IgM and IgG immune response to WNV infection are presented with respect to the day of illness.

(Pealer et al., 2003; Montgomery et al., 2006), screening of blood and organ donations obtained from persons living in WNV endemic areas is important to identify samples that are infected with WNV (Pisani et al., 2016).

Diagnosis of WNV Acute Infection

In recent years, the detection of viral genome in bodily fluids by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) has become the routine diagnosis method for many viral infections due to its industry standard format, high levels of repeatability and reproducibility, high sensitivity and specificity, fast turnaround time and ease of use (Boonham et al., 2014). Unfortunately, for most diseases caused by flaviviruses, including WNV, molecular diagnosis by qRT-PCR of serum, plasma and cerebrospinal fluid (CSF) samples is of limited value for routine diagnosis due to low level and short lived viremia generated by these viruses (Busch et al., 2006, 2008; Barzon et al., 2013a; Lustig et al., 2016; Figure 1). Recently, several studies have demonstrated that WNV is retained in the kidneys and can therefore be detected in urine samples for a longer period of time than plasma, CSF or serum (Barzon et al., 2013a,b, 2014, 2015). In addition, since WNV was shown to adhere to red blood cells (Rios et al., 2007) it can persist for months in whole blood of blood donors (Lanteri et al., 2014). We have recently found that during acute WNV infection WNV RNA can be detected in whole blood, serum, CSF, plasma, and urine samples in 86.8, 26, 16.6, 20 and 58.3% of WNV infected patients, respectively, demonstrating the superiority and effectiveness of WNV RNA detection in whole blood for diagnosis of acute Infection (Lustig et al., 2016; Figure 1). Several commercial and in house molecular diagnostic tests with varying sensitivities are available which are different primarily in their amplification target of the viral genome.

Blood and Organ Screening

Transmission of WNV during blood and organ donations has been recorded in the United States (Gyure, 2009) and Europe (Morelli et al., 2010; Costa et al., 2011; Rabel et al., 2011; Inojosa et al., 2012). As mentioned previously, 80% of WNV infections in humans are asymptomatic and most persons are not aware they have been infected with WNV, especially in areas endemic for WNV (Hayes et al., 2005). Therefore, screening of blood donations for WNV is performed annually in many countries with WNV endemic circulation, such as the United States, Canada, several countries in the European Union and Israel to assess and reduce the risk of organ transplant and blood recipients for infection with WNV. A few commercial nucleic acid amplification tests (NATs) are on the market which are approved for blood testing from healthy persons (Pai et al., 2008; Ziermann and Sanchez-Guerrero, 2008; Zhang et al., 2009), are fully automated, and allow testing on hundreds of plasma samples a day. Due to the low levels of WNV RNA that may be present in healthy, asymptomatic blood donors, these commercial tests need to detect WNV with very high sensitivity and specificity.

SEROLOGICAL WNV DIAGNOSIS

Due to the challenges with WNV viral detection, specific antibody testing is currently the most widely used approach for WNV diagnosis. Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies can usually be detected by day 4 and day 8 after onset of symptoms, respectively (Busch et al., 2008) and therefore detection of IgM antibodies alone or IgG seroconversion can point to a WNV acute infection (Figure 1). Numerous commercial kits for WNV antibody detection are available.
which are primarily based on detection of specific antibodies against the Envelope (E) protein of WNV using either enzyme linked immunosorbertent assays (ELISAs) or immunofluorescence tests (IFAs). The advantages of these qualitative assays are that they are very easy to use in a laboratory setting, the results are mostly reproducible and part of their protocol can be automated. However, since WNV IgM can persist in serum for months and even years after infection (Prince et al., 2005; Busch et al., 2008; Murray et al., 2010, 2013; Papa et al., 2011, 2015) and significant cross reactivity exists between all flaviviruses it is often difficult to diagnose acute WNV infection based on these commercial kits alone. To validate the initial results neutralization assays can be used. Neutralization determines the ability of the antibodies present in the patient's sample to neutralize the virus and therefore it can evaluate the antibody-virus neutralization efficiency (Nelson et al., 2008) and is considered the gold standard for diagnosis of WNV infection (Calisher et al., 1989; Kuno, 2003). There are several types of neutralization protocols with similar performance which differ in their sensitivity [plaque reduction neutralization (PRNT) 50 or PRNT90], the method of cytopathic effect (CPE) detection (direct, staining, detection with IFA) and the plates used (for PRNT or micro-neutralization).

The Zika epidemic, which emerged in 2015 in Brazil (Fauci and Morens, 2016; Song et al., 2017), poses another layer of complication for diagnosis of flaviviruses, including WNV. Due to the high cross-reactivity of Zika virus with other flavivirus antibodies, E protein based ELISAs and neutralization assays encounter difficulties to distinguish between specific flavivirus infections and as a result diagnosis of WNV or dengue virus (Lanciotti et al., 2008; Balmaseda et al., 2017) in persons with Zika virus background is more challenging. Our experience (unpublished results) with Zika positive patients show high cross reactivity with WNV E protein based ELISAs which can cause false positive results for encephalitic patients and as a consequence the wrong treatment. The development of ELISA tests for Zika infection which use the Non-structural 1 (NS1) protein as antigen for Zika antibody testing proved to be advantageous and more specific than E protein based ELISAs (Steinhagen et al., 2016), however, sensitivity and detection times issues, especially in countries with previous dengue (Steinhagen et al., 2016) and possibly WNV (Lustig et al., 2017c) background limit the dependence on this test. Development of similar NS1 antibody based ELISA assays for WNV and dengue virus could be useful in reducing the cross-reactivity resulting in more specific Flavivirus diagnostic tests.

NOVEL METHODS FOR WNV DETECTION

Serological methods aided by detection of viral nucleic acid by qRT-PCR will, most probably, continue to be the primary and preferred diagnostic methods for WNV. Nevertheless, the establishment of next generation sequencing (NGS) methods in recent years, which are also called deep or high-throughput sequencing, led to the increased use of NGS to complement diagnosis and monitoring of infectious diseases caused by both bacteria (Deurenberg et al., 2017) and viruses (Hoper et al., 2016; Casadella and Paredes, 2017; Ramamurthy et al., 2017). The most important diagnostic application for NGS is probably the unbiased identification of pathogens in clinical samples. With regards to WNV, one example is the identification of WNV by NGS from a CSF sample obtained from a 14 years old meningoencephalitis patient (Wilson et al., 2017). In a recent study, plasma samples from 12 cases of unexplained febrile illness in Tanzania were investigated by NGS and identified WNV in two samples (Williams et al., 2018). These examples demonstrate the additive value that NGS may provide even in diagnosis of viruses with short viremia such as WNV. NGS can also be used in epidemiological investigations and research (Zana et al., 2016).

Recently, a new and novel method for the detection of flavivirus RNAs including Zika, dengue and WNV from body fluids has emerged. Using CRISPR-cas13 technology, a fluorescent protein was used to track and detect flavivirus RNAs present in patients samples generating a field-deployable viral diagnostic platform with high performance and minimal equipment or sample processing requirements (Myhrvold et al., 2018). This platform is comparable in its sensitivity to qRT-PCR assays, is fast (under 2 h) and may be used to serve as a diagnostic platform in areas with limited resources or even compete with current molecular diagnostic devices which are in the market.

CONCLUDING REMARKS

The emergence and geographical spread of WNV in recent years has forced endemic countries to initiate integrated surveillance programs to identify, predict, and reduce WNV circulation. Future programs should be implemented to combine all data and assess the effectiveness of these surveillance programs to reduce the burden of WNV infections. In addition, due to the influx of other flaviviruses, such as Zika virus, and their global expansion, more specific, yet sensitive assays for WNV diagnosis should be established to be able to distinguish between the different diseases and ultimately pave the way for the development of a WNV vaccine.

AUTHOR CONTRIBUTIONS

YL reviewed the design, researched the literature, and wrote and edited the manuscript. DS researched the literature and edited and provided critical review of the manuscript. EB researched the literature and wrote and edited the manuscript. EM reviewed the design, researched the literature, and edited and provided critical review of the manuscript.

FUNDING

This work was supported by internal sources of the Central Virology Laboratory.
Ergunay, K., Bakonyi, T., Nowotny, N., and Ozkul, A. (2015). Close relationship between West Nile virus from Turkey and lineage 1 strain from Central African Republic. Emerg. Infect. Dis. 21, 352–355. doi: 10.3201/eid2102.141135
Ergunay, K., Gunay, F., Erioso, Kasap, O., Oter, K., Gargari, S., Karaoglu, T., et al. (2014). Serological, molecular and entomological surveillance demonstrates widespread circulation of West Nile virus in Turkey. PLoS Negl. Trop. Dis. 8:e3028. doi: 10.1371/journal.pntd.0003028
Ergunay, K., Gunay, F., Oter, K., Kasap, O. E., Orsten, S., Akcutay, A. Z., et al. (2013). Arboviral surveillance of field-collected mosquitoes reveals circulation of West Nile virus lineage 1 strains in Eastern Thrace, Turkey. Vector Borne Zoon. Dis. 13, 744–752. doi: 10.1089/vbz.2012.1288
Ergunay, K., Littba, N., Brinkmann, A., Gunay, F., Sarikaya, Y., Kar, S., et al. (2017). Co-circulation of West Nile virus and distinct insect-specific flaviviruses in Turkey. Parasit. Vectors 10:149. doi: 10.1186/s13071-017-2087-7
Fauci, A. S., and Morens, D. M. (2016). Zika Virus in the Americas—Yet Another Arbovirus Threat. N. Engl. J. Med. 374, 601–604.
Figueroa, J., Soriguier, R., Rojo, G., Gomez Tejedor, C., and Jimenez-Clavero, M. A. (2017). Surveillance and Diagnosis of West Nile Virus. J. Neuropathol. Exp. Neurol.
Figuerola, J., Soriguer, R., Rojo, G., Sarikaya, Y., Kar, S., et al. (2017). Pathology and tissue tropism of natural West Nile virus infection in birds: a review. Vet. Res. 46:39. doi: 10.1186/1297-9716-44-39
Garcia-Bocanegra, I., Arenas-Montes, A., Napp, S., Jaen-Tellez, J. A., Fernandez-Morente, M., Fernandez-Molera, V., et al. (2012). Seroprevalence and risk factors associated to West Nile virus in horses from Andalusia, Southern Spain. Vet. Microbiol. 160, 341–346. doi: 10.1016/j.vetmic.2012.06.027
Gaitani, P., Pierro, A., Lunghi, G., Farina, C., Toschi, V., Matinato, C., et al. (2013). Seroprevalence of West Nile virus antibodies in blood donors living in the metropolitan area of Milan, Italy, 2009-2011. New Microbiol. 36, 81–83.
Gambino, V., and Hofle, U. (2013). Arboviral surveillance of field-collected mosquitoes reveals circulation of West Nile virus in humans and mosquitoes in Spain, 2010. Emerg. Infect. Dis. 17, 2397–2399. doi: 10.3201/eid1711.100651
Giordano, B. V., Kaur, S., and Hunter, F. F. (2017). West Nile virus in the Americas—Yet Another Arbovirus Threat. N. Engl. J. Med. 374, 601–604.
Giordano, B. V., Kaur, S., and Hunter, F. F. (2017). West Nile virus in the Americas—Yet Another Arbovirus Threat. N. Engl. J. Med. 374, 601–604.
Giordano, B. V., Kaur, S., and Hunter, F. F. (2017). West Nile virus in the Americas—Yet Another Arbovirus Threat. N. Engl. J. Med. 374, 601–604.
Gomes, B., Kioulos, E., Papa, A., Papamichail, D., Mourelatos, S., et al. (2013). Population seroprevalence study after a West Nile virus lineage 2 epidemic, Greece, 2010. PLoS One 8:e80432. doi: 10.1371/journal.pone.0080432
Lanciotti, R. S., Kosoy, O. L., Laven, J. J., Velez, J. O., Lambert, A. J., Johnson, A. J., et al. (2008). Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14, 1232–1239. doi: 10.3201/eid1408.080027
Lanciotti, R. S., Roehrig, I. T., Deubel, V., Smith, J., Parker, M., Steele, K., et al. (1999). Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286, 2333–2337.
Lanteri, M. C., Lee, T. H., Wen, L., Kaidarova, Z., Bravo, M. D., Kiely, N. E., et al. (2014). West Nile virus nucleic acid persistence in whole blood months after clearance in plasma: implication for transfusion and transplantation safety. Transfusion 54, 3232–3241. doi: 10.1111/trf.12764
Leland, D. S., and Cinoccio, C. C. (2007). Role of cell culture for virus detection in the age of technology. Clin. Microbiol. Rev. 20, 49–78.
Lerner, H., and Berg, C. (2015). The concept of health in One Health and some practical implications for research and education: what is One Health? Infect. Ecol. Epidemiol. 5:23500. doi: 10.3402/iee.v5.25300
Li, R., Shi, J., Wu, J., and Zhu, H. (2006). Modeling spatial spread of west nile virus and impact of directional dispersal of birds. Math. Biosci. Eng. 3, 145–160.
Lopez, G., Jimenez-Clavero, M. A., Tejedor, C. G., Soriguier, R., and Figuerola, J. (2008). Prevalence of West Nile virus neutralizing antibodies in Spain is related to the behavior of migratory birds. Vector Borne Zoon. Dis. 8, 615–621. doi: 10.1089/vbz.2007.0200
Lopez-Ruiz, N., Montano-Remacha, M. D. C., Duran-Pla, E., Perez-Ruiz, M., Navarro-Mari, J. I., Salamanca-Rivera, C., et al. (2018). West Nile virus outbreak in humans and epidemiological surveillance, west Andalusia, Spain, 2016. Euro. Surveill. 23:00261.
Lustig, Y., Hindiyeh, M., Orshan, L., Weiss, I., Koren, R., Katz-Likvornik, S., et al. (2015). Fifteen years of mosquito surveillance reveals high genetic diversity of West Nile Virus in Israel. J. Infect. Dis. 213, 1107–1114.
Lustig, Y., Kaufman, Z., Mannesse, B., Koren, R., Katz-Likvornik, S., Orshan, L., et al. (2017a). West Nile virus outbreak in Israel in 2015: phylogenetic and geographic characterization in humans and mosquitoes. Clin. Microbiol. Infect. 23, 986–993. doi: 10.1016/j.cmi.2017.04.023
Lustig, Y., Mannesse, B., Koren, R., Katz-Likvornik, S., Hindiyeh, M., Mandelboim, M., et al. (2016). Superiority of West Nile Virus RNA Detection in Whole Blood for Diagnosis of Acute Infection. J. Clin. Microbiol. 54, 2294–2297. doi: 10.1128/JCM.01283-16
Lustig, Y., Kaufman, Z., Mendelson, O., Orshan, L., Anis, E., Glazer, Y., et al. (2017b). Spatial distribution of West Nile virus in humans and mosquitoes in Israel, 2000-2014. Int. J. Infect. Dis. 64, 20–26. doi: 10.1016/j.ijid.2017.08.011
Lustig, Y., Zelena, H., Venturi, G., Van Esbroeck, M., Rothe, C., Perret, C., et al. (2017c). Sensitivity and Kinetics of an NS1-Based Zika Virus Enzyme-Linked Immunosorbent Assay in Zika Virus-Infected Travelers from Israel, the Czech Republic, Italy, Belgium, Germany, and Chile. J. Clin. Microbiol. 55, 1894–1901. doi: 10.1128/JCM.00346-17
Mackenzie, J. S., Gubler, D. J., and Petersen, L. R. (2004). Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10, S98–S109.

Maidana, N. A., and Yang, H. M. (2009). Spatial spreading of West Nile virus described by traveling waves. J. Theor. Biol. 258, 403–417. doi: 10.1016/j.jtbi.2008.12.032

Malkinson, M., and Banet, C. (2002). The role of birds in the ecology of West Nile virus in Europe and Africa. Curr. Top. Microbiol. Immunol. 267, 309–322.

Mallya, S., Sander, B., Roy-Gagnon, M. H., Taljaard, M., Jolly, A., and Kulkarni, M. A. (2018). Factors associated with human West Nile virus infection in Ontario: a generalized linear mixed modelling approach. BMC Infect. Dis. 18:141. doi: 10.1186/s12879-018-3052-6

May, F. J., Davis, C. T., Tesh, R. B., and Barrett, A. D. (2011). Phylogeography of West Nile virus: from the cradle of evolution in Africa to Eurasia, Australia, and the Americas. J. Virol. 85, 2964–2974. doi: 10.1128/JVI.01963-10

Montgomery, S. P., Brown, J. A., Kuehnert, M., Smith, T. L., Crall, N., Lanciotti, R. S., et al. (2006). Transfusion-associated transmission of West Nile virus, United States 2003 through 2005. Transfusion 46, 2038–2046.

Morelli, M. C., Sambri, V., Grazi, G. L., Gaibani, P., Pierro, A., Cescon, M., et al. (2010). Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. Clin. Infect. Dis. 51, e34–e37. doi: 10.1086/655146

Mulatti, P., Bonfanti, L., Capelli, G., Capello, K., Lorenzetto, M., Terregino, C., et al. (2013). West Nile virus in north-eastern Italy, 2011: entomological and equine IgM-based surveillance to detect active virus circulation. Zoon. Public Health 60, 375–382. doi: 10.1111/zph.12013

Murray, K., Walker, C., Herrington, E., Lewis, J. A., McCormick, J., Beasley, D. W., et al. (2010). Persistent infection with West Nile virus years after initial infection. J. Infect. Dis. 201, 2–4. doi: 10.1086/648731

Murray, K. O., Garcia, M. N., Yan, C., and Gorchakov, R. (2013). Persistence of detectable immunoglobulin M antibodies up to 8 years after infection with West Nile virus. Am. J. Trop. Med. Hyg. 89, 996–1000. doi: 10.4269/ajtmh.13-0232

Myhrvold, C., Freije, C. A., Gootenberg, J. S., Abudayyeh, O. O., Metyka, H. C., Durbin, A. F., et al. (2018). Field-deployable viral diagnostics using CRISPR-Cas13. Science 360, 444–448. doi: 10.1126/science.aaw836

Napolì, C., Bella, A., Declich, S., Grazzini, G., Lombardini, L., Nanni Costa, A., et al. (2013). Integrated human surveillance systems of West Nile virus infections in Italy: the 2012 experience. Int. J. Environ. Res. Public Health 10, 7180–7192. doi: 10.3390/ijerph10071780

Nash, D., Mostashari, F., Barzon, L., Cusinato, R., Cattai, M., Pacenti, M., et al. (2011). Prevalence of IgM and IgG antibodies to West Nile virus among blood donors in an affected area of north-eastern Italy, summer 2009. Euro. Surveill. 16:19814

Papa, A., Gibaini, P., Maniserca, C., Dirani, G., Rossini, G., Cavirini, F., et al. (2011). Seroprevalence of West Nile virus-specific antibodies in a cohort of blood donors in northeastern Italy. Vector Borne Zoon. Dis. 11, 1605–1607. doi: 10.1089/vbz.2011.0616

Pierre, A., Gaibani, P., Spadafora, C., Ruggeri, D., Randi, V., Parenti, S., et al. (2013). Detection of specific antibodies against West Nile and Usutu viruses in healthy blood donors in northern Italy, 2010-2011. Clin. Microbiol. Infect. 19, E451–E453. doi: 10.1111/1469-0691.12241

Pisani, G., Cristiano, K., Papulla, S., and Liimbruno, G. M. (2016). West Nile Virus in Europe and Safety of Blood Transfusion. Transfus Med. Hemother. 43, 158–167. doi: 10.1159/000446219

Poh, K. C., Martin, E., Walker, E. D., Kitron, U., Ruiz, M. O., Goldberg, T. L., et al. (2018). Co-circulation of Flanders Virus and West Nile Virus in Culex Mosquitoes (Diptera: Culicidae) from Chicago, Illinois. J. Med. Entomol. 55, 1062–1066.

Prince, H. E., Toblier, L. H., Lape-Nixon, M., Foster, G. A., Stramer, S. L., and Bushc, M. P. (2005). Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. J. Clin. Microbiol. 43, 4316–4320.

Rabel, P. O., Planitzer, C. B., Farcet, M. R., Orlinger, K. K., Ilk, R., Barrett, P. N., et al. (2011). Increasing West Nile virus antibody titres in central European plasma donors from 2006 to 2010. Euro. Surveill. 16:19692

Ramamurthy, M., Sankangi, R., Nanjagopal, B., and Sridharan, G. (2017). Application of viromics: a new approach to the understanding of viral infections in humans. Virusdisease 28, 349–359. doi: 10.1007/s13370-017-0415-3

Rappole, J. H., and Hubalek, Z. (2003). Migratory birds and West Nile virus. J. Appl. Microbiol. 94 (Suppl.), 475–585.

Reisen, W. K., Takahashi, R. M., Carroll, B. D., and Quiring, R. (2008). Delinquent mortgages, neglected swimming pools, and West Nile virus, California. Emerg. Infect. Dis. 14, 1747–1749. doi: 10.3201/eid1411.080719

Rios, M., Daniel, S., Chancey, C., Hewlett, I. K., and Stramer, S. L. (2007). West Nile Virus adheres to human red blood cells in whole blood. Transfusion Med. Hemother. 309–322.

Rosa, R., Marini, G., Bolzoni, L., Neteler, M., Metz, M., Delucchi, L., et al. (2014). Early warning of West Nile virus mosquito vector: climate and land use models successfully explain phenology and abundance of Culex pippins mosquitoes in north-western Italy. Parasit. Vectors 7:269. doi: 10.1186/1756-3305-7-269
Ruiz, M. O., Walker, E. D., Foster, E. S., Haramis, L. D., and Kitron, U. D. (2007). Association of West Nile virus illness and urban landscapes in Chicago and Detroit. *Int. J. Health Geogr.* 6:10.

Salama, M., Amidan, Z., Lustig, Y., Mor, Z., Weberger, M., Chowers, M., et al. (2018). Outbreak of West Nile Virus disease in Israel (2015): a retrospective analysis of notified cases. *Travel Med. Infect. Dis.* doi: 10.1016/j.tmaid.2018.07.008 [Epub ahead of print].

Sanchez-Gomez, A., Amela, C., Fernandez-Carrion, E., Martinez-Aviles, M., Sanchez-Vizcaino, J. M., and Sierra-Moros, M. J. (2017). Risk mapping of West Nile virus circulation in Spain, 2015. *Acta Trop.* 169, 163–169. doi: 10.1016/j.actatropica.2017.02.022

Seino, K. K., Long, M. T., Gibbs, E. P., Bowen, R. A., Beachboard, S. E., Humphrey, P. P., et al. (2007). Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model. *Clin. Vaccine Immunol.* 14, 1465–1471.

Simeone, R. M., Shapiro-Mendoza, C. K., Meaney-Delman, D., Petersen, E. E., Galang, R. R., Odueyo, T., et al. (2016). Possible Zika Virus Infection Among Pregnant Women - United States and Territories, May 2016. *MMWR Morb. Mortal. Wkly. Rep.* 65, 514–519. doi: 10.15585/mmwr.mm6520e1

Song, B. H., Yun, S. I., Woolley, M., and Lee, Y. M. (2017). Zika virus: history, epidemiology, transmission, and clinical presentation. *J. Neuroimmunol.* 308, 50–64. doi: 10.1016/j.neuroim.2017.03.001

Steiner, I., and Kennedy, P. G. (2013). West Nile virus introduction into the New World. *Neurology* 81, 1441–1442.

Steinhagen, K., Probst, C., Radzimski, C., Schmidt-Chanasit, J., Emmerich, P., van Elbroeck, M., et al. (2016). Serodiagnosis of Zika virus (ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a multicohort study of assay performance, 2015 to 2016. *Euro. Surveill.* 21:30426.

Stiasny, K., Aberle, S. W., and Heinz, F. X. (2013). Retrospective identification of human cases of West Nile virus infection in Austria (2009 to 2010) by serological differentiation from Usutu and other flavivirus infections. *Euro. Surveill.* 18:20614.

Tesh, R. B., Parsons, R., Sirin, M., Randle, Y., Sargent, C., Guzman, H., et al. (2004). Year-round West Nile virus activity, Gulf Coast region, Texas and Louisiana. *Emerg. Infect. Dis.* 10, 1649–1652.

Turell, M. J., Dohm, D. J., Sardelis, M. R., Oguinn, M. L., Andreantis, T. G., and Blow, J. A. (2005). An update on the potential of north American mosquitoes (Diptera: culicidae) to transmit West Nile Virus. *J. Med. Entomol.* 42, 57–62.

Valiakos, G., Papaspyropoulos, K., Giannakopoulos, A., Birtsas, P., Tsiodras, S., Huchtings, M. R., et al. (2014). Use of wild bird surveillance, human case data and GIS spatial analysis for predicting spatial distributions of West Nile virus in Greece. *PloS One* 9:e96935. doi: 10.1371/journal.pone.0096935

Vanlandingham, D. L., McGee, C. E., Klenger, K. A., Vesney, N., Fredregillo, C., and Higgs, S. (2007). Relative susceptibilities of South Texas mosquitoes to infection with West Nile virus. *Am. J. Trop. Med. Hyg.* 77, 925–928.

Vrioni, G., Mavrouli, M., Kapsimali, V., Stavropoulou, A., Detsis, M., Danis, K., et al. (2014). Laboratory and clinical characteristics of human West Nile virus infections during 2011 outbreak in southern Greece. *Vector Borne Zoon. Dis.* 14, 52–58. doi: 10.1089/vbz.2013.1369

Weinberger, M., Pitlik, S. D., Gadacu, D., Lang, R., Nassar, F., Ben David, D., et al. (2001). West Nile fever outbreak, Israel, 2000: epidemiologic aspects. *Emerg. Infect. Dis.* 7, 686–691.

White, D. J., Kramer, L. D., Backenson, P. B., Lukacik, G., Johnson, G., Oliver, J. A., et al. (2001). Mosquito surveillance and polymerase chain reaction detection of West Nile virus, New York State. *Emerg. Infect. Dis.* 7, 643–649.

Williams, S. H., Cordey, S., Bhuva, N., Laubscher, F., Hartley, M. A., Boillat-Blanco, N., et al. (2018). Investigation of the Plasma Virome from Cases of Unexplained Febrile Illness in Tanzania from 2013 to 2014: a Comparative Analysis between Unbiased and VirCapSeq-VERT High-Throughput Sequencing Approaches. *mSphere* 3:e00311-18.

Wilson, M. R., Zimmermann, L. L., Crawford, E. D., Sample, H. A., Soni, P. R., Baker, A. N., et al. (2017). Acute west nile virus meningoencephalitis diagnosed via metagenomic deep sequencing of cerebrospinal fluid in a renal transplant patient. *Am. J. Transplant.* 17, 803–808. doi: 10.1111/ajt.14058

Zana, B., Kemenesi, G., Herczeg, R., Dallos, B., Oldal, M., Marton, S., et al. (2016). Genomic characterization of West Nile virus strains derived from mosquito samples obtained during 2013 Serbian outbreak. *J. Vector Borne Dis.* 53, 379–383.

Zhang, W., Wu, J., Li, Y., Li, F., and Njoo, H. (2009). Rapid and accurate in vitro assays for detection of West Nile virus in blood and tissues. *Transfus Med. Rev.* 23, 146–154. doi: 10.1016/j.tmrv.2008.12.008

Zheng, H., Drebot, M. A., and Coulthart, M. B. (2014). West Nile virus in Canada: ever-changing, but here to stay. *Can. Commun. Dis. Rep.* 40, 173–177.

Ziermann, R., and Sanchez-Guerrero, S. A. (2008). PROCLEIX West Nile virus assay based on transcription-mediated amplification. *Expert Rev. Mol. Diagn.* 8, 239–245. doi: 10.1586/14737159.8.3.239

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.